FORTREA HOLDINGS DL-,001 Aktie Logo
US34965K1079
A3ECGB
FTRE

FORTREA HOLDINGS DL-,001 Aktie

Wczytywanie kursów wyceny...

Prognoza

Średnia cena docelowa analityków wynosi 21,33 € (+19,16%). Mediana wynosi 21,38 € (+19,44%).

Kupuj
  7
Trzymaj
  5
Sprzedaj
  1

Dyskusje w społeczności

Nie ma jeszcze dyskusji o tym aktywie.

Rozpocznij dyskusję

  • Fortrea cooperates with Omico to accelerate biomarker-driven cancer trials in Australia

    Fortrea has announced a collaboration with Omico to advance precision oncology research by accelerating the identification and matching of suitable patients to biomarker-driven clinical trials. The partnership combines Fortrea’s expertise in running oncology studies with Omico’s PrOSPeCT platform, molecular profiling data and a network of investigators and trial sites in Australia. The aim is to optimize study design, enable more targeted site selection and speed patient recruitment using genomic data from more than 23,000 patients. » Więcej na finanzen.net


  • Fortrea completes acquisition of Worldwide Clinical Trials' early phase services business

    Fortrea has closed the purchase of Worldwide Clinical Trials' early phase services division for about $45 million. The deal includes a 200-bed CRU in San Antonio, a 60,000 sq ft GLP bioanalytical lab in Austin and a sample storage facility in Pflugerville. The acquisition brings Fortrea's global early-phase capacity to more than 570 beds and strengthens internal bioanalytical capabilities to better integrate clinical and analytical processes. It is intended to shorten turnaround times, reduce operational handoffs and expand the platform for clinical development. » Więcej na finanzen.net


  • Fortrea buys early-phase unit from Worldwide for $45 million

    Fortrea has signed an agreement to acquire the early‑phase division of Worldwide Clinical Trials for about $45 million in cash. The acquisition includes a 60,000‑square‑foot bioanalytical lab in Austin, a 200‑bed clinic in San Antonio and a biospecimen storage facility in Pflugerville. Fortrea thereby strengthens its Clinical Pharmacology Services and expands capacity for bioanalysis of large and small molecules, while the transaction still requires regulatory and licensing approvals. Both companies plan transition agreements to ensure continuity for customers and ongoing programs. » Więcej na de.investing.com


  • Fortrea introduces Fortrea Intelligent Technology, an AI-powered suite to accelerate clinical trials

    Fortrea has introduced Fortrea Intelligent Technology (FIT), a suite of people-centered, AI-powered solutions to automate workflows, optimize monitoring, and accelerate clinical trials. FIT builds on the Xcellerate platform and offers applications for biopharma, biotechnology, and medical device companies in full-service, functional-service, and SaaS models. The suite is organized into three pillars — lifecycle, foresight, and support — and provides role-based insights in near real time to improve predictability, quality, and productivity. » Więcej na finanzen.net


  • Fortrea launches AI-powered technology suite Fortrea Intelligent Technology to support clinical trials

    Fortrea introduced Fortrea Intelligent Technology (FIT), an AI-powered suite that includes extensions to the Xcellerate platform and new Lifecycle, Foresight and Companion modules. The tools automate workflows, integrate study data for role-specific insights and use AI/ML for pattern analysis and predictive signal generation; selected components will be offered as SaaS. The announcement comes as the stock trades below $10 and analysts project a return to profitability. » Więcej na de.investing.com

Dane finansowe spółki

W ostatnim kwartale FORTREA HOLDINGS DL-,001 Aktie osiągnęła przychody w wysokości 610,49 mln € i zysk netto w wysokości 529,71 tys. €
(EUR) wrzesień 2026
YoY
Przychody 610,49 mln 2,16%
Zysk brutto 123,16 mln 40,18%
Zysk netto 529,71 tys. 103,91%
EBITDA 32,31 mln 180,88%

Dane fundamentalne

Wskaźnik Wartość
Kapitalizacja rynkowa
1,69 mld €
Liczba akcji
94,6 mln
Maksimum/minimum z 52 tygodni
23,80 € - 7,78 €
Dywidendy Nie
Beta
1,86
C/Z (PE Ratio)
-25,99
PEG (PEG Ratio)
-0,11
C/WK (PB Ratio)
3,52
C/S (PS Ratio)
0,69

Profil spółki

Fortrea Holdings Inc. świadczy usługi w zakresie rozwoju klinicznego i dostępu pacjentów do rozwiązań dla branży nauk o życiu. Oferuje zarządzanie badaniami klinicznymi faz I–IV, farmakologię kliniczną, zróżnicowane rozwiązania do prowadzenia badań oparte na technologii oraz usługi posprzedażowe po uzyskaniu zatwierdzenia. Firma obsługuje organizacje farmaceutyczne, biotechnologiczne i producentów wyrobów medycznych. Fortrea Holdings Inc. ma siedzibę w Durham w Karolinie Północnej.

Nazwa
FORTREA HOLDINGS DL-,001 Aktie
CEO
Anshul Thakral
Siedziba Durham, nc
Stany Zjednoczone
Strona internetowa
Branża
Ochrona zdrowia: sprzęt i produkty
Debiut giełdowy
20.06.2023
Pracownicy 14 000

Symbole giełdowe

Giełda Symbol
NASDAQ
FTRE
Frankfurt
K67.F
Düsseldorf
K67.DU
München
K67.MU
🍪

Parqet  używa plików cookie. Dowiedz się więcej